Lipid Trp-L1-T4
Instructions for Use
Product information
Trp-L1-T4 is an L-tryptophan-derived ionizable lipid selected as the core lipid in the study's TLNP platform for self-amplifying RNA delivery to follicular helper T cells. The base TLNP formulation produced 59.8% GFP-positive primary Tfh cells under the reported in vitro conditions. In targeted variants, the authors combined CXCR5-antibody functionalization, Tfh-restricted RNA translation and, for in vivo work, Tween-20 modification to generate regulatory CAR-Tfh cells and evaluate a preclinical autoimmune-hepatitis model. These outcomes depend on the complete formulation, targeting ligand, RNA design and study conditions. All formulation and performance information shown below is literature-derived evidence, not a product specification or a guarantee of reproducible LNP performance.
| CAS No. | Not available |
| Chemical Name | Lipid Trp-L1-T4 |
| Formula | C41H74N4O |
| M.Wt | 639.07 |
| Purity | >95% by ELSD-HPLC |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
Formulation & study context
Literature information refers to the cited study and its particular formulation. Administration routes are research context, not clinical instructions or a guarantee of performance.
| Component | Reported molar ratio | Role |
|---|---|---|
| Trp-L1-T4 | 25 | Ionizable lipid |
| Cholesterol | 20 | Sterol |
| DMG-PEG2000 | 0.5 | PEG lipid |
| DOPE | 10 | Helper phospholipid |
| Reported ratio sum | 55.5 | Original ratio retained |
| N/P ratio | Not reported in the cited article |
| Total lipid:cargo weight ratio | 10:1 ionizable lipid:saRNA (w/w) in the main text; Supplementary Figure S1D labels the optimized axis as total lipids:mRNA, creating a terminology ambiguity |
| Buffer & pH | 10 mM citrate aqueous phase, pH 3; post-mixing dialysis against PBS |
| Cargo | GFP self-amplifying RNA (saRNA) |
| Administration route | In vitro Tfh-cell transfection for the lead TLNP result; targeted therapeutic variants were given intravenously |
| Dose | 80 ng GFP-saRNA per 50,000 Tfh cells |
| Animal model | Primary mouse follicular helper T cells for lead screening |
| Formulation process | Staggered-herringbone microfluidic mixing at 3:1 aqueous:ethanol flow-rate ratio; 2 h dialysis through a 10 kDa membrane, concentration with a 100 kDa filter and 0.22-micrometer filtration; stored at 4 degrees C. |
N/P is the molar ratio of specified lipid nitrogen groups to nucleic-acid phosphate groups. A lipid:cargo mass ratio is a different quantity and must not be used as N/P.
Stock-solution preparation table
Calculated from the product-page molecular weight: 639.07 g/mol. Volumes are final solution volumes.
| Lipid mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 15.648 mL | 3.130 mL | 1.565 mL |
| 25 mg | 39.119 mL | 7.824 mL | 3.912 mL |
| 50 mg | 78.239 mL | 15.648 mL | 7.824 mL |
| 100 mg | 156.477 mL | 31.295 mL | 15.648 mL |
| 250 mg | 391.193 mL | 78.239 mL | 39.119 mL |
Volume (mL) = mass (mg) × 1000 / [MW (g/mol) × concentration (mM)]. These are mathematical conversions, not measured solubility or validated solvent recommendations. Confirm solvent compatibility and the molecular weight of the exact material before use.
Open editable solution calculators →Handling & storage
Provided that storage conditions are as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 1 year.
Wherever possible, prepare and use solutions on the same day. If stock solutions must be prepared in advance, store them as aliquots in tightly sealed vials at -20°C. Generally, these will be usable for up to one month.
Before use, and prior to opening the vial, allow the product to equilibrate to room temperature for at least 1 hour.
References
Cited literature for this formulation and performance dataset Zheng Z, Liu Y, Wang G, et al. In vivo CAR-Tfh cell reprogramming restores tolerance in a mouse model of autoimmune hepatitis. Cell Stem Cell. 2026;33:589-604. DOI: 10.1016/j.stem.2026.02.006 Structure and lead selection: main Figure 1 and Supplementary Figure S1; base formulation: main text and Supplementary Table S1; preparation: STAR Methods; particle properties: Supplementary Table S2; targeted CAR-Tfh performance and mouse AIH-II studies: main Figures 2-7 and Supplementary Figures S2-S7.